Kintor Pharmaceutical Limited announced that the topline results of phase III clinical trial of KX-826 topical treatment for male androgenetic alopecia have been read out. This Phase III Clinical Trial is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topical use of KX-826 twice daily at a concentration of 0.5% in the treatment of male AGA adults in China. The main endpoint of this study is the average change in non-vellus target area hair counts (the TAHC) compared to baseline at the end of 24 weeks.

Safety endpoints include the type, incidence, and severity of adverse events. The results showed that the overall safety of the trial was good, with KX-826 demonstrating excellent safety profile and no serious adverse events was reported. After 24 weeks' treatment, TAHC of the treatment group showed that KX-826 promoted hair growth compared to baseline, with statistical significance (P<0.0001).

Compared with placebo, there was TAHC improvement at all visit points in KX-826 group with no statistical significance, but a trend in efficacy was observed. The Company will continue to analyze the results of the Phase III Clinical Trial in the future, and the group will further conduct multiple clinical trials of KX-826 for topical treatment of AGA and acne, exploring the possibility of the commercialization of KX-826.